(AOF) – The consolidated turnover of the Safe group stands at 5.6 million euros for the year 2023, down 3.6% compared to 2022. The medtech in receivership since the 4 September 2023 specifies that direct sales of Safe Orthopedics amount to 3.1 million euros, compared to 3.7 million euros in 2022, while Safe Medical is up 17% with a turnover of 2.5 million euros versus 2.1 million euros in 2022.
“Driven by a new strategy and the determination of the new management team”, the group wants to “return to sustainable and profitable growth”.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.